Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models.
Li D, Geng K, Hao Y, Gu J, Kumar S, Olson AT, Kuismi CC, Kim HM, Pan Y, Sherman F, Williams AM, Li Y, Li F, Chen T, Thakurdin C, Ranieri M, Meynardie M, Levin DS, Stephens J, Chafitz A, Chen J, Donald-Paladino MS, Powell JM, Zhang ZY, Chen W, Ploszaj M, Han H, Gu S, Zhang T, Hu B, Nacev BA, Kaiza ME, Berger AH, Wang X, Li J, Sun X, Liu Y, Zhang X, Bruno TC, Gray NS, Nabet B, Wong KK, Zhang H.
Li D, et al. Among authors: levin ds.
J Clin Invest. 2024 Dec 24:e174249. doi: 10.1172/JCI174249. Online ahead of print.
J Clin Invest. 2024.
PMID: 39718828
Free article.